Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.

Li, Zheqi; Spoelstra, Nicole S; Sikora, Matthew J; Sams, Sharon B; Elias, Anthony; Richer, Jennifer K; Lee, Adrian V; Oesterreich, Steffi

Li, Zheqi; Spoelstra, Nicole S; Sikora, Matthew J; Sams, Sharon B; Elias, Anthony; Richer, Jennifer K; Lee, Adrian V; Oesterreich, Steffi.

Affiliation

Li Z; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Spoelstra NS; Women's Cancer Research Center, Magee Women's Research Institute, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Sikora MJ; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Sams SB; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Elias A; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Richer JK; School of Medicine, Division of Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Lee AV; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Oesterreich S; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.

NPJ Breast Cancer ; 8(1): 62, 2022 May 10.

Article de En | MEDLINE | ID: mdl-35538119

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: NPJ Breast Cancer Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google